Immuno-oncology Market Size, Share, Trends, Analysis and Forecast by Region, Segment, Type (Checkpoint Modulators, Cancer Vaccines) and End-User (Hospitals, Cancer Research Institute), 2022-2030

LONDON, UK, October 24, 2022 /EINPresswire.com/ -- The global immuno-oncology market was worth nearly $45,121.62 million in 2021. The immuno-oncology market is expected to grow at a more than CAGR of 20% over the next 10 years. Major factors such as an increase in healthcare expenditure, a rise in the prevalence and incidence of cancer, a surge in technological advancement in cancer treatment, and novel product launches are expected to boost market growth during the forecast period.

View Report Outlook at: https://www.globaldata.com/store/report/immuno-oncology-market-trend-analysis/

The immuno-oncology market report offered by GlobalData Plc provides an overview of the immuno-oncology market size & forecast by class, end-user, and geography. It also helps us understand the immuno-oncology value chain and identify the key vendors in the market.

Learn about the Immuno-oncology Market Dynamics by Viewing Report Sample Right Here!

Immuno-oncology Market Report Highlights

• The global immuno-oncology market is projected to witness a CAGR of 20.30% from 2021 to 2030, reaching a value of $238.19 billion. Major factors such as an increase in healthcare expenditure, a rise in prevalence and incidence of cancer, a surge in technological advancement in cancer treatment, and novel product launches are expected to boost the market growth during the forecast period
• In 2021, the checkpoint modulators segment of the immuno-oncology market is estimated at US$36.45 billion in 2021 and is forecast to reach US$191.38 billion by 2030, growing at a CAGR of 20.23%.
• The hospitals segment of the immuno-oncology market is estimated at $37.22 billion in 2021 and is expected to grow up to $195.64 billion by 2030, growing at a CAGR of 20.25%.
• North America closely followed by Europe captured over 60% of the overall immuno-oncology share in 2021. The rise in cancer incidence, approval of novel drug therapies, increasing funding and investment for the development of immuno-oncology drugs, and an increase in strategic partnerships are the major factors contributing to the market growth.
• The immuno-oncology market key players analyzed as part of this report are Amgen, AstraZeneca, Roche, among others

Unlock additional market dynamics impacting the immuno-oncology market growth by Requesting a Sample PDF

GlobalData Plc has segmented the immuno-oncology market report by class, End-user, and region:

Global immuno-oncology class Outlook (Revenue, USD Million, 2022-2030)
• Checkpoint Modulators
• Cancer vaccines
• Cell Therapies
• Bispecific antibodies
• Cytokines
• Oncolytic Viruses

Global immuno-oncology end-user Outlook (Revenue, USD Million, 2022-2030)
• Hospitals
• Cancer Research Centers
• Others

Immuno-oncology market outlook report with detailed segment analysis is available with Global Data Now! Make a Purchase Right Here!

Global Immuno-oncology Regional Outlook (Revenue, USD Million, 2022-2030)
• North America
• US
• Canada
• Mexico

• Europe
• UK
• Germany
• France
• Italy
• Spain
• Rest of Europe

• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia Pacific

• ROW
• UAE
• Saudi Arabia
• Brazil
• Rest of ROW

About us
GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision-makers to predict and navigate the future. GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on us for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.

Media Contacts

Mark Jephcott
GlobalData Plc
+44 20 7936 6400
mark.jephcott@globaldata.com
Visit us on social media:
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.